Can opioid exacerbate acute lung injury via TLR4?

2017 Fiscal Year Final Research Report

• Project/Area Number: 26462760
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Emergency medicine
• Research Institution: Kyoto Prefectural University of Medicine
• Principal Investigator: Matsuyama Hiroki 京都府立医科大学, 医学(系)研究科(研究院), 客員講師 (80515289)
• Co-Investigator(Kenkyū-buntansha): 天谷 文昌 京都府立医科大学, 医学(系)研究科(研究院), 准教授 (60347466)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: オピオイド / acute lung injury / 免疫細胞

Outline of Final Research Achievements

We investigated the effect of remifentanil on the inflammatory reaction in the lung during acute lung injury.
Remifentanil was continuously infused to rats. Remifentanil dose was determined based on the behavioral assessment of withdrawal hyperalgesia. Expression of inflammatory cytokines in the lung of rats treated with LPS with or without remifentanil was measured by real time PCR. Opioid receoptor and TLR5 expression in the lung was investigated by immunohistochemistry.
LPS induced induction of inflammatory cytokine in the lung. The effect of remifentanil on the LPS induced induction of inflammatory cytokine was not clear. We detected cells positive for opioid receptors or TLR4 in the lung tissue.

Free Research Field

集中治療